News >

Vaccine Shows Signs of Stimulatory Effects in Early-Stage CRC

Caroline Seymour
Published: Wednesday, May 08, 2019

Karen E. Knudsen, PhD

Karen E. Knudsen, PhD

A vaccine targeting GUCY2C, a commonly overexpressed protein in patients with early-stage colorectal cancer (CRC), induced antibody and T-cell responses toward the specified target and demonstrated an acceptable safety profile in this patient population, according to results of a first-in-human phase I trial (NCT01972737).1,2

“The goal of the study to begin this fall is to show that version 2.0 of the vaccine is even better and that it may benefit a much bigger group of the overall cancer patient population,” Snook said in the press release.


  1. Snook A, Baybutt T, Xiang B, et al. Split tolerance permits safe AD5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. J Immunother Can. 2019;7(104). doi: 10.1186/s40425-019-0576-2.
  2. Novel Vaccine for Colorectal Cancer Shows Positive Phase I Results. Jefferson Health. Published April 29, 2019. Accessed April 30, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication